Method of producing nitrogen-containing organic compounds

专利摘要:
There are described compounds of the formula in which R' is hydrogen or C1-6 alkyl, R2 is hydrogen, C1-6 alkyl or C3-6 alkenyl, R3 is hydrogen or C1-6 alkyl, R4 is hydrogen or an N-protecting group, n is 2, 3, 4 or 5, and X is oxygen, sulphur or -CH2-, provided that when X is -CH2- n is 0; and salts thereof. The compounds in which R4 is hydrogen have pharmaceutical activity.
公开号:SU1376944A3
申请号:SU843824680
申请日:1984-12-13
公开日:1988-02-23
发明作者:Джеймс Стегглс Дэвид；Помфрет Вердж Джон
申请人:Лилли Индастриз Лимитед (Фирма)；
IPC主号:

专利说明:

The invention relates to a process for the preparation of new nitrogen-containing organic compounds of the general formula
GL CH, CO-Q-0- (
BUT СНтСН СН- and
where n is 2, 3, 4, or 5, vle ynshch with leukotriene inhibitors.
The purpose of the invention is to obtain new tetrazole derivatives with a different spectrum of biological properties than the known ones.
The method is carried out as follows.
Preparation of Compound (i) 1- | 2-ox-3-propyl-4- 3- (4-nitrophenoxy) propoxy-phenyl-ethanone
To sodium hydride (71 g, 50% dispersion) in dry dimethylformamide (200 ml), 2,4-dioxy-3-propyl acetophenone (24.6 g) was added to dimethyl sodium (5.5 g). The reaction mixture was left under stirring for 20 hours, allowed and evaporated under reduced pressure until a residue was obtained in the form of a brown oil. The oil is collected in water, extracted three times with dich methane, washed twice with 2N. ra
Diluted with sodium hydroxide and sodium thiosulfate, dried over magnesium sulfate, filtered and evaporated under reduced pressure until a solid is obtained.
5 brown. The solid is recrystallized twice from methanol, thus obtaining a yellow crystalline substance, b.p. 124-125 ° C.
20 In a similar way, the following compounds are obtained: - | 2-hydroxy-3-nap-4-4- (4-nitrophenoxy) butox; phenyl | ethanone, mp. 103-105 ° C (1- {2-hydroxy-3-propyl-4- 5- (4-nitr
thirty
35
formamide (20 mp) by prokapyvany 25 phenoxy) pentoxy-phenyl ethanone, in a nitrogen atmosphere. Obtained in re-C (EtOH). As a result, the solution is heated to 100 ° C, after which 4-nitro-1- (3-chlorproxy) benzene (27.3 g) and sodium iodide (19.0 g) are quickly added. The reaction mixture is left under stirring overnight at 100 ° C, cooled and distilled off under reduced pressure to obtain a brown oil. The oil is collected in water, extracted twice with dichloromethane, washed with 2 aqueous sodium hydroxide solution, then with aqueous sodium thiosulfate solution, dried over magnesium sulfate, filtered and evaporated under reduced pressure to obtain a dark brown solid. The solid is recrystallized from methanol using activated carbon to obtain the desired product in the form of needles of a pale yellow color, m.p. 98 ° C.
Preparation of compound (ii) hydroxy-3-propyl-4- 2- (4-nitrophenoxy) ethoxy-phenyl ethanone,
To sodium hydride (1.78 g, 50% dispersion) in dry dimethylformamide (60 ml), 2,4-dioxy-3-propyl acetophenone (72 g) in dimethylformamide (20 ml) is added dropwise under nitrogen. The solution is heated to 100 ° C and 4-nitro-1- (2-chloro-ethoxy) benzene (7.5 g) and iodide are quickly added to it.
Preparation of Compound (iii) 1 hydroxy-3-propyl-4- 3- (4-aminopheno propoxy-phenyl} ethanone,
1- {2-Oxy-3-propyl-4- - (4-n-phenoxy) propoxy-phenyl} zg non (19.6 g) is dissolved in a mixture of this (300 ml) and dimethylformamide (100 to the resulting solution, add under a nitrogen atmosphere, a suspension of ladie on a catalyst of active carbon (1.0 g, 5%) in ethanol (50 ml), the Suslenzia is then irradiated on a Parr device at d 40 scientific research institute 60 pounds per square inch
(4.22 kg / cm) at room temperature for 90 minutes. The suspension is filtered on cellite, washed with ethanol and the filtrate is evaporated under reduced pressure to obtain a brown color, which is powdered with water and filtered to obtain a brown solid. The solid is recrystallized from nola with activated charcoal and at the same time solid logo is colored, so pl. 7.5-77 Co
Preparation of compound (iv) 1oxy-3-propyl-4- 2- (4-aminopheno ethoxy1-phenyl} ethanone „
1- {2-Oxy-3-propyl-4- 2- (4-n-phenoxy) ethoxy-phenyl ethanone (6 is dissolved in a mixture of ethanol (250
45
50
55
sodium (5.5 g). The reaction mixture is left under stirring at a temperature for 20 hours, cooled and evaporated under reduced pressure to obtain the residue as a brown oil. The oil is taken up in water, extracted three times with dichloromethane, washed twice with 2N. sodium hydroxide solution and sodium thiosulfate aqueous solution, dried over magnesium sulfate, filtered and evaporated under reduced pressure to obtain a solid.
Brown color. The solid is recrystallized twice from methanol, thus obtaining a yellow crystalline substance, b.p. 124-125 ° C.
In a similar manner, the following compounds are obtained: - | 2-hydroxy-3-propyl-4- 4- (4-nitrophenoxy) butoxy-phenyl | ethanone, m.p. 103-105 ° C (MeOH), 1- {2-hydroxy-3-propyl-4- 5- (4-nitro-phenoxy) pentoxy-phenyl ethanone, C (EtOH).
0
five
5 Phenoxy) pentoxy-phenyl ethanone, C (EtOH).
Preparation of Compound (iii) 1- {2- hydroxy-3-propyl-4- 3- (4-aminophenoxy) propoxy-phenyl} ethanone,
1- {2-Oxy-3-propyl-4- - (4-nitrophenoxy) propoxy-phenyl} zg non (19.6 g) is dissolved in a mixture of ethanol (300 ml) and dimethylformamide (100 ml), to the resulting the solution is added under a nitrogen atmosphere to a suspension of palladium on an activated carbon catalyst (1.0 g, 5%) in ethanol (50 ml), and the suspension is then hydrogenated on a Parr device at a pressure of 60 psi
(4.22 kg / cm) at room temperature for 90 minutes. The suspension is filtered on cellite, washed with ethanol and the filtrate is evaporated under reduced pressure to obtain a brown oil, which is triturated with water and filtered to obtain a brown solid. The solid is recrystallized from ethanol with activated charcoal and you get a white solid, so pl. 7.5-77 Co
Preparation of Compound (iv) 1 {2-hydroxy-3-propyl-4- 2- (4-aminophenoxy) ethoxy1-phenyl} ethanone „
1- {2-Oxy-3-propyl-4- 2- (4-nitrophenoxy) ethoxy-phenyl ethanone (6.0 g) is dissolved in a mixture of ethanol (250 ml)
five
0
five
31376944
and dimethylformamide :. (60 ml), to grow
a suspension of palladium on activated carbon (500 mg, 5%) in ethanol (50 ml) is added to the thief under nitrogen atmosphere. The suspension is then hydrogenated on a Parr device at a pressure of 60 pounds per square inch at room temperature for 2 hours. The suspension is filtered pressure to obtain a brown solid. The solid is recrystallized from ethanol to obtain a cream-colored solid, m.p. 73-74 ° C.
The following compounds are prepared in a similar manner: 1 - {2-hydroxy-3-propyl-4-4- (4-aminophenoxy) butoxy-phenyl ethanone; 1-2-hydroxy-3-propyl-4- 5- (4- aminophenoxy) pentoxy-phenyl | ethane, so pl. 70-72 ° C (EtOH).
Example 1. (4-Acetyl-3-hydroxy-2-propylphenoxy) propoxy - phenylJ-1- (4-methoxyphenylmethyl) -1H-tetrazole-5-carboxamide „
1- (4-Methoxyphensh1methyl) -1H-tetrazole-5-potassium carboxylate (10 g) and pyridine (1.8 ml) are mixed together in dry toluene (140 ml) at 10 ° C. Oxalyl chloride (30.7 ml) is added dropwise and the mixture is stirred at 15 ° C for 1 hour. The suspension is filtered and the remaining solid is washed with dry toluo. scrap (100 ml). The filtrate and the washing are then evaporated under reduced pressure and temperature. Below to obtain an acidic chloride of an insidious yellow color, which is dissolved in dyshormethane (20 ml) and added dropwise m-1 to 2-hydroxy-3- Above-4-3-aminophenoxy) propoxy phenyl ethanone (12.5 g) and pyridine j (2.8 mp) in dry dichloromethane (140 ml) at 10 ° C. After the addition, the mixture is heated to 25 ° C for 24 hours, washed twice with water (150 ml), then saturated brine (100 ml), dried over magnesium sulphate, filtered and evaporated under reduced pressure, thus obtaining a brown solid. the substance is triturated with ether, filtered and recrystallized from acetonitric to obtain a pale brown solid, m.p. 122-125 C. Example 2. (4-Acetyl-3-hydroxy-2-propylphenoxy) ethoxy J-phenyl j - 1 - (4-methoxyphenylmethyl) -1H-tetrazole-5-carboxamide.
Potassium 1- (4-methoxyphenylmethyl) -1H-tetrazole-5-carboxylate (6.28 g) and pyridine (1.1 mp) are stirred in dry toluene (90 ml) at 10 ° C. Oxalyl chloride (19.3 ml) is added and the mixture is stirred at 15 ° C for 1 hour. The suspension is filtered and the residue is taken up in dry toluene. The combined residue and solution for
The 5 washes were evaporated under reduced pressure at a temperature below 30 ° C to obtain an acidic yellowish acid chloride, which was dissolved in dry dichloromethane (20 ml) and
0 dropping it to 1- | 2-hydroxy-3-propyl-4- 2- (4-aminophenoxy) ethoxy-phenyl ethanone (7.6 g) and pyridine (1.7 ml) in dry dichloromethane (100 ml) at. After adding
5 the mixture is allowed to warm to
 for 18 h, washed twice with water (100 ml), then saturated brine (100 ml), dried over magnesium sulfate, filtered
0 and evaporated under reduced pressure. To give a pale brown solid. The solid is recrystallized from acetonitrile, thereby obtaining a solid
five
substance pale yellow.
m.p. 123-225 C.
The following compounds are prepared in an analogous manner: (4-acetyl-.3-oxy-2-propylphenoxy) bytoxy-3-fe- (4-methoxyphenylmethyl) -1H-tetrazole-5-carboxamide, m.p. 111- (), (4-acetyl-3-hydroxy-2-propylphenoxy) pentoxy-pephenyl | -1- (4-methoxyphenylmethyl) -1H-tetrazole-5-carboxamide, m.p. 107-110 ° C (CH-CN).
Example 3. H- {4- 3- (4-Acetyl-3-hydroxy-2-propylphenoxy) propoxy-phenyl) -1H-tetrazole-5-carboxamide.
A solution of 1- (4-methoxyphenylmethyl) tetrazole-5-carboxamide (3 g) and anisole (2.2 g) in trifluoroacetic acid (30 nl) is heated under reflux for 2 hours. The cooled solution is evaporated under reduced pressure until a brown solid remains, which is stirred with ether for 30 microns, filtered and
0
dried to obtain a pale brown solid. The solid is recrystallized from ethanol to obtain a yellowish-brown crystalline solid, t, pl. 200-202 ° C.
Example 4. N (4-Acetyl-3-hydroxy-2-propylphenoxy) ethoxy 3 phenyl-Sh-tetrazole-3-carboxamide
A solution of 1- (4-methoxyphenylmethyl) tetrazole-5-carboxamide (4.5 g) and anisole (3.3 g) in trifluoroacetic acid (43 ml) is heated under reflux for 2 hours and then the solvent is distilled off under reduced pressure . The residue is stirred with ether for 30 minutes and filtered to obtain a brown solid, which is recrystallized from ethanol, thus obtaining a solid, yellowish-brown crystalline substance, ToPLs 201-203 ° C.
In a similar way, the following mixture is prepared: N - 4- (4- (4-acetyl-3-oxy-2-propyl-phenoxy) bytoxy-J-fenche | -1H-tetrazole-5-carboxamide, mp. 190 191 ° C (EtOH); N - ((4-acetyl-3-hydroxy-2-propylphenoxy) pentoxy and 3-phenyl-1H-tetrazole-5-carboxamide, mp 142-1440 ° C ().
The following examples illustrate the preparation of typical formulations containing a pharmacologically active substance in accordance with the invention.
Example 5. Aerosol: active ingredient 100 mg, ethanol 30 ml; substance that provides movement 12/14, q .S.
The active ingredient is dissolved in ethanol, poured into glass bottles, sealed with a valve (allowing measurement to 0.05 ml) and charged with mixed substances to eject the contents.
Example 6. Tablet: active ingredient 100 mg, dry starch 400 mg; polyvinyl pyrrolidone 50 mg; carboxymethyl sodium starch 30 mg, stearic acid 20 mg.
The active ingredient and starch are mixed together, the resulting mass is mixed with a solution of polyvinylpyrrolidone in alcohol. The mass is passed through a sieve, dried, imparted
five
five
Q
about
0
five
0
five
0
five
size and blend with sodium carboxymethyl starch and stearic acid before compression in a tablet machine. You get tablets weighing 620 mg.
Example 7. Capsules: active ingredient 30 mg; flowable starch 300 mg silicone fluid 3 mg.
A portion of the starch is mixed with a silicone liquid. The active ingredient and the remaining amount of starch are added to the powder. This mixture is introduced into hard gelatin capsules.
The compounds according to the invention are pharmacologically active, are inhibitors of leukotriene effects, which was shown during tests in vitro on a fragment of the ileum of the guinea pig at concentrations from 10 ng to 50 µg in accordance with the method of Skilda, using LTD, as an antagonistic compound The proposed compounds exhibit ICp relative to LTD, at a concentration of less than 10 mol.%, shown in vivo in the study of the pulmonary function of the marine pig: the Osten and Drazen methods in intravenous administrations of 0.05 µg to 5.0 mg / kg and, during the modified test, Herxheimer at doses ranging from 25 to 200 mg / kg. The Herxheimer test is based on bronchospasm created in guinea pigs using LTDj, which resembles an asthma attack in humans. The compounds according to the invention also suppressed the formation of leukotrienes, which is confirmed by their behavior in the experiment described by Harvey and Osborn.
The known compound (4-acetyl-3-hydroxy-2-methylphenoxy) propoxy7 benzoic acid provides 1C - value for a guinea pig in a test on the ileum 18 µmol, which is much less active compared to the compounds of the proposed invention. .
The proposed dinene compounds have the following ICcQ values, µmol:
Connection example:
3 0,2
40.1 4 (first optional connection) 0.1 4 (second additional connection) 1.2

权利要求:
Claims (1)
[1]
The compounds of the present invention were tested by analyzing the behavior of animals in an aerosol application of the active compound to guinea pigs at a dose of 0.1 mg / ml. None of the compounds exerted a toxic effect. Formula of gain
The method of obtaining nitrogen-containing organic compounds of the formula
cHjCo-Q o-f.CHzVo-O Icouno CHzCHjCH,
where p is 2,3,4 or 5 different compound of the formula
Y
H
topics what
where r
H I
HN
0- {CH2 ri-0- -toH (N CHjCH, g
N is a protective group.
is reacted with trifluoro-acetic acid in anisole at the boiling point of the reaction mixture.

类似技术:

---

公开号 | 公开日 | 专利标题

---

Young et al.1988|Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists

---

EP0125783B1|1989-01-04|Dopamine-beta-hydroxylase inhibitors

---

JP3468738B2|2003-11-17|A therapeutic agent for hypercholesterolemia or atherosclerosis

---

IE57700B1|1993-03-10|Chemical compounds

---

EP0190472A1|1986-08-13|New pharmaceutical compositions having anti-psychotic properties

---

CA2195427A1|1996-02-01|Novel aryl piperazine-derived piperazide derivatives, methods for their preparation, their use as drugs and pharmaceutical compositions comprising same

---

US6762176B1|2004-07-13|2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them

---

SU1597098A3|1990-09-30|Method of producing heterocyclic carboxamides

---

CA1161853A|1984-02-07|N-lower-alkyl 3-phenoxy-1-azetidine-carboxamides

---

SU1376944A3|1988-02-23|Method of producing nitrogen-containing organic compounds

---

DE602004009056T2|2008-06-19|N- | SULFAMIDE DERIVATIVES AS INTEGRIN ALPHA4 ANTAGONISTS

---

CA1247101A|1988-12-20|5-alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3-onecompounds, intermediates and methods for theirpreparation, and pharmaceutical compositionscontaining them

---

DE2109910A1|1971-09-16|N, N disubstituted ammosaic compounds

---

Baggaley et al.1985|Inhibitors of blood platelet aggregation. Effects of some 1, 2-benzisothiazol-3-ones on platelet responsiveness to adenosine diphosphate and collagen

---

EP0643697A1|1995-03-22|Quaternary pyridinium compounds

---

SK279199B6|1998-07-08|N,n'-bis-|-pyridine-2,4-dicarboxylic acid diamides, a process of preparation and use thereof, pharmaceutical compositions containing the same

---

CH629781A5|1982-05-14|METHOD FOR PRODUCING benzenesulfonylureas.

---

US4514408A|1985-04-30|N-substituted nicotinamide 1-oxide as histamine H2 receptor blockers

---

JPH07233162A|1995-09-05|Imidazolidinone derivative, its acid addition salt and therapeutic agent for senile dementia

---

DE2737738A1|1978-03-09|DERIVATIVES OF 3-MINOTHIOPHEN-4-CARBONIC ACID, MANUFACTURING METHOD AND MEDIUM CYCLIC COMPOUNDS

---

KR960016123B1|1996-12-04|Di-t-butyl phenyl alkyl and benzyl ethers

---

CA1075714A|1980-04-15|Biologically active amides

---

US5208252A|1993-05-04|Aminoethylthiophene derivatives

---

DE2412520A1|1974-10-10|TRICYCLIC LINKS

---

EP2001846A1|2008-12-17|Indole derivatives as inhibitors of the soluble adenylate cyclase

同族专利:

---

公开号 | 公开日

---

DK596784D0|1984-12-13|

---

PL144287B1|1988-05-31|

---

PT79650A|1985-01-01|

---

HUT36807A|1985-10-28|

---

HU192090B|1987-05-28|

---

DK596784A|1985-06-17|

---

IL73776A|1988-02-29|

---

ES8702379A1|1986-12-16|

---

JPS60146880A|1985-08-02|

---

AU3668384A|1985-06-20|

---

ES538365A0|1986-12-16|

---

GB2151227B|1987-09-03|

---

GB8333665D0|1984-01-25|

---

PT79650B|1986-12-22|

---

GR81223B|1985-04-11|

---

NZ210502A|1987-03-06|

---

FI844849L|1985-06-17|

---

US4675333A|1987-06-23|

---

IL73776D0|1985-03-31|

---

GB8431229D0|1985-01-23|

---

ZA849677B|1986-04-30|

---

CA1228857A|1987-11-03|

---

KR850004470A|1985-07-15|

---

PH21750A|1988-02-18|

---

PL250868A1|1985-07-30|

---

FI844849A0|1984-12-07|

---

EP0147973A1|1985-07-10|

---

GB2151227A|1985-07-17|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

NL7810634A|1977-10-28|1979-05-02|May & Baker Ltd|TETRAZOLE DERIVATIVES.|

---

GB2006782B|1977-10-28|1982-06-16|May & Baker Ltd|Tetrazole derivatives|

---

NZ194844A|1979-09-05|1983-07-29|Glaxo Group Ltd|Phenoxyalkoxyphenyl derivatives and pharmaceutical compositions|

---

EP0056172B1|1981-01-09|1985-04-03|FISONS plc|Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them|

---

US4567201A|1981-11-25|1986-01-28|Takeda Chemical Industries, Ltd.|Diphenoxypropane derivatives and compositions of antiasthmatic and antiinflammatory agents thereof|

---

US4499299A|1981-12-30|1985-02-12|Ici Americas Inc.|Pharmaceutically active phenylcarboxylic acid derivatives|

---

AU548915B2|1983-02-25|1986-01-09|Toyota Jidosha Kabushiki Kaisha|Plasma treatment|EP0165897B1|1984-05-24|1989-03-15|Ciba-Geigy Ag|Resorcin ethers|

---

PT81492B|1985-09-17|1988-03-03|Ciba Geigy Ag|METHOD FOR PREPARING NEW FLORORATED RESORCINE ETEREES|

---

US4808604A|1985-10-03|1989-02-28|Ciba-Geigy Corporation|N- tetrazol-5-yl carboxamides and anti-allergic use thereof|

---

PT81374B|1985-10-25|1988-02-17|Ciba Geigy Ag|PROCESS FOR THE PREPARATION OF NEW ETERES OF RESORCINE|

---

GB8800099D0|1988-01-05|1988-02-10|May & Baker Ltd|New chemical process|

---

DE3829431A1|1988-08-31|1990-03-01|Boehringer Mannheim Gmbh|SULPHONAMID WITH TETRAZOLYL RESIDUE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS|

---

JP2527488Y2|1990-09-10|1997-02-26|三菱アルミニウム株式会社|Retort food packaging bag|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

GB838333665A|GB8333665D0|1983-12-16|1983-12-16|Organic compounds|

---